RAC1 and head and neck squamous cell carcinoma: Our findings provide evidence for further clinical investigation of the potential sensitivity of RAC1-amplified and RAC1-A159V-mutant HNSCC to Rac inhibitors, when such inhibitors become clinically available for human trials.